Increased inactive creatine kinase B protein in the plasma of patients with malignancy.
Using a specific radioimmunoassay for enzymically inactive creatine kinase (EC 2.7.3.2) B protein (CK-Bi), we studied 139 patients with various malignancies. We found it to be increased in certain adenocarcinomas, including colorectal, lung, and prostate, as has also been reported for enzymically active CK-BB. Of 15 patients with leukemia or lymphomas with active disease, 12 also had increased values for CK-Bi in plasma. In these patients, concentrations of CK-Bi in plasma tended to correlate with disease activity, increasing with aggressive malignancy and decreasing on successful treatment. Thus, measurement of CK-Bi may constitute a sensitive means for detecting malignancy and, in certain subsets of patients, for monitoring therapeutic response.
D000230:Adenocarcinoma / Q000201:enzymology; D000328:Adult; D000368:Aged; D003402:Creatine Kinase / Q000097:blood*; D005260:Female; D006801:Humans; D007527:Isoenzymes; D007938:Leukemia / Q000201:enzymology; D008223:Lymphoma / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000201:enzymology*; D011863:Radioimmunoassay
D007527:Isoenzymes; D003402:Creatine Kinase